CN1315533C - Inactivate pig parvovirus disease oil emulsion vaccine - Google Patents
Inactivate pig parvovirus disease oil emulsion vaccine Download PDFInfo
- Publication number
- CN1315533C CN1315533C CNB2004100254396A CN200410025439A CN1315533C CN 1315533 C CN1315533 C CN 1315533C CN B2004100254396 A CNB2004100254396 A CN B2004100254396A CN 200410025439 A CN200410025439 A CN 200410025439A CN 1315533 C CN1315533 C CN 1315533C
- Authority
- CN
- China
- Prior art keywords
- vaccine
- oil
- oil emulsion
- inactivated
- porcine parvovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The present invention relates to an inactivated oil-emulsion porcine parvovirus vaccine capable of preventing sow reproductive disturbance resulted from porcine parvovirus (PPV), which belongs to the technical field of novel veterinary biomedicines. The inactivated oil-emulsion porcine parvovirus vaccine is prepared by inoculating porcine parvovirus for cell culture, and then adding oil adjuvant to the obtained virus liquid for emulsification after being inactivated with an alkylating agent. The oil adjuvant measured by volume capacity is prepared by that aluminum stearate is added to the mixed liquid of 94 wt% of white oil and 6 wt% of span-80, namely that each 2g of aluminum stearate is added to 100 milliliter mixed liquid. The present invention solves the technical problems that the existing vaccines have poor stability, rapid demixing, short shelf lives, etc. by changing the formula of the oil adjuvant, and overcomes the defects that the existing vaccines are inconvenient for use, etc. by reducing the doses and using times of the vaccines through technical research.
Description
Technical field:
The invention belongs to the biological new medicine technical field of veterinary, particularly a kind of pig parvoviral oil emulsion inactivated vaccine can prevent the sow breeding difficulty disease that is caused by pig parvoviral (PPV).
Background technology:
Original pig parvoviral AEI inactivated vaccine is that+pig parvoviral (PPV) inoculating cell is cultivated, and the viral liquid of acquisition adds oily adjuvant through the formulated two-phase oil emulsion vaccine of emulsifying after the AEI deactivation.This immune effect of vaccine is good, but has the following disadvantages and problem:
1, the less stable of vaccine, layering are fast, and the Emulsion Seedling is divided into two layers of milky and pale reds very soon after preserving, and can fold a small amount of oil reservoir on emulsion face upper strata, and the outward appearance physical behavior is not good enough, and breakdown of emulsion takes place in the shelf-life sometimes, has influenced vaccine quality.Main cause wherein is the problem of oily adjuvant, and the oily adjuvant of preparation vaccine is formed (petrolatum: lanoline=9: 1) by petrolatum and lanoline.
2, occur inappetence sometimes after the pig body vaccinate, spirit is not good enough, have also can generate heat, untoward reaction such as allergy, inoculation position is obviously red and swollen.The main cause that causes is relevant with oily adjuvant, and is also relevant greatly with the dosage of vaccine use.
3, the dosage of this vaccine use is that 1 pig will be injected 2 times, each 5 milliliters, and two weeks of interval, 10 milliliters of accumulated doses.For this reason, the user is reflected the formality trouble that vaccine uses, and increases the labor intensity of epidemic prevention.
Summary of the invention:
The invention provides the pig parvoviral inactivated vaccine-pig parvoviral oil emulsion inactivated vaccine behind a kind of optimize.By changing the prescription of oily adjuvant, solve technical problems such as fast and shelf-life of less stable, the layering of existing product vaccine, keeping under the reliable prerequisite of immune effect of vaccine, reduce the using dosage of vaccine and reduce access times, solve weak points such as using the formality trouble.
For solving the problems of the technologies described above, the present invention is achieved in that
A kind of pig parvoviral oil emulsion inactivated vaccine, it is characterized in that: be that the pig parvoviral with the alkylating agent deactivation is added oily adjuvant is formulated through emulsifying, oily adjuvant preparation is that to add 2 gram aluminium stearate after the Si Ben-80 with 94% volume white oil and 6% volume mixes in again according to above-mentioned 100 milliliters of mixed liquors formulated.
Adopt a step emulsifying.
Adopt two step method emulsifying.
Immunizing dose is 2 milliliters of every pig muscle injections.
The present invention has following technique effect:
1, improves the physical behavior of vaccine, improve vaccine quality, adopt new oily adjuvant preparation vaccine, make the outward appearance of vaccine and physical behavior be improved significantly, the oily adjuvant of forming with white oil, Si Ben-80 and aluminium stearate is an oil phase, and adding 2% tween in the virus is water, can make viscosity＜2 by two-step emulsification method "; stability is better preserved the not two-phase of breakdown of emulsion (W/O/W) oil emulsion inactivated vaccine at 4 ℃.Thereby the method and the standard of check vaccine physical behavior have been set up.
2, dosage of Shi Yonging and number of times reduce.The usage and dosage of original vaccine is intramuscular injection 2 times, each 5 milliliters, and two weeks of interval; The usage and dosage of optimizing vaccine is 2 milliliters of 1 intramuscular injection.
The specific embodiment:
A kind of pig parvoviral oil emulsion inactivated vaccine, be that the pig parvoviral (PPV) of deactivation is added oily adjuvant is to add aluminium stearate in the liquid surely closing of forming according to percentage by weight 94% white oil and 6% Si Ben-80 through the formulated oily adjuvant of emulsifying, its addition is 100 milliliters and surely closes liquid and add 2 gram aluminium stearate.
The amount that contains aluminium stearate in the oil adjuvant is relevant with the stability of vaccine, and carrying out repeatedly emulsification test proves, when containing the 1-1.5% aluminium stearate in the oily adjuvant, the vaccine of preparation is through 3000r.p.m after centrifugal 15 minutes, can divide two layers, the upper strata milky, lower floor's pale red capacity accounts for 2/5-3/5; When containing 2% aluminium stearate, after 3000r.p.m 15 minutes is centrifugal, divide two layers, lower floor accounts for 1/5-1/6; When containing 4%, the viscosity of vaccine obviously increases, and a spot of white precipitate can occur.
Using the oily adjuvant (being made up of 9 parts of petrolatums and 1 part of lanoline) that uses originally instead white oil is the main oily adjuvant of forming.Through repeatedly comparing, (outward appearance, viscosity, stability, dosage form etc.) have evident difference aspect physical behavior, also are like this even adopt different emulsification methods to the vaccine of these two kinds oily adjuvants preparations.No matter adopting one-step method emulsifying with new oily adjuvant still is two step method emulsifying, vaccine was placed 1-2 days at normal temperatures, very a spot of pale red emulsion only appears in the bottle end of 5000 milliliters of vaccine loading amounts, vaccine stability with old oily adjuvant preparation is relatively poor, layering is fast, and the vaccine for preparing just can be divided into two layers soon.
Inactive Oil-emulsion Porcine Parvovirus Vaccine inoculation 2-3 age in days neonatal rat through optimizing, safety is passed through.The back all produces antibody response, HI:128～1024 around the inoculation Cavia porcellus.Inoculating 6 batches of responsive pigs does not have obvious adverse reaction, and body temperature, appetite are normal, and inoculation portion does not have obvious red and swollen piece.
By safety and the immunity test of this animal, immune duration and storage life are tested, and have confirmed the effect of less vaccine consumption and number of times.
Original vaccine usage and dosage is intramuscular injection 2 times, each 5 milliliters, and two weeks of interval.By test, the usage and dosage of optimizing vaccine is defined as 2 milliliters of 1 intramuscular injection.
Concrete result of use of the present invention sees also following table:
| The vaccine title | Type | Immunizing dose | Immune time | Use | Safety * | Physical behavior | Immunity | Storage life (4-12 ℃) | Duration of immunity |
| The pig parvoviral oil emulsion inactivated vaccine | Optimize the back vaccine | 2ml/ time | 1 time | Convenient | Better | Better | 94％ | At least 7 months | 6 months |
| Pig parvoviral AEI inactivated vaccine | Original vaccine (optimize) | 5ml/ time | 2 times | Trouble | Weak point is arranged | Not good enough | 94.1％ | At least 7 months | 6 months |
*Safety: referring to have denys non-specific untoward reaction: inoculation position has or not obvious red and swollen piece, and whether appetite, spirit, body temperature is normal.
In sum, through transform and optimize after the pig parvoviral oil emulsion inactivated vaccine not only obviously be better than original vaccine in the stability and the safety of outward appearance and physical behavior, vaccine, and immunizing dose reduces 5 times, immune time is kept to 1 time, the immune effect of vaccine is certain, every immunity index is constant, thereby greatly reduces cost, has made things convenient for the user.
Claims (4)
1, a kind of pig parvoviral oil emulsion inactivated vaccine, it is characterized in that: be that the pig parvoviral with the alkylating agent deactivation is added oily adjuvant is formulated through emulsifying, oily adjuvant preparation is that to add 2 gram aluminium stearate after the Si Ben-80 with 94% volume white oil and 6% volume mixes in again according to above-mentioned 100 milliliters of mixed liquors formulated.
2, pig parvoviral oil emulsion inactivated vaccine according to claim 1 is characterized in that: adopt a step emulsifying.
3, pig parvoviral oil emulsion inactivated vaccine according to claim 1 is characterized in that: adopt two step method emulsifying.
4, pig parvoviral oil emulsion inactivated vaccine according to claim 1 is characterized in that: immunizing dose is 2 milliliters of every pig muscle injections.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100254396A CN1315533C (en) | 2004-06-24 | 2004-06-24 | Inactivate pig parvovirus disease oil emulsion vaccine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100254396A CN1315533C (en) | 2004-06-24 | 2004-06-24 | Inactivate pig parvovirus disease oil emulsion vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1706497A CN1706497A (en) | 2005-12-14 |
| CN1315533C true CN1315533C (en) | 2007-05-16 |
Family
ID=35580728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100254396A Active CN1315533C (en) | 2004-06-24 | 2004-06-24 | Inactivate pig parvovirus disease oil emulsion vaccine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1315533C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101851609B (en) * | 2010-02-02 | 2012-10-03 | 哈药集团生物疫苗有限公司 | Porcine parvovirus L strain and use thereof in preparation of porcine parvovirus inactivated vaccines |
| CN107802830A (en) * | 2017-10-19 | 2018-03-16 | 吉林农业科技学院 | A kind of pig parvoviral disease vaccine emulsification method based on mineral oil adjuvant |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1141810A (en) * | 1995-06-02 | 1997-02-05 | 美国家用产品公司 | Viral vaccine |
| DE20219829U1 (en) * | 2002-12-20 | 2003-05-08 | Danmarks Veterinaeinstitut Kop | Vaccine formulation against bacterial, viral, mycotic, prion or parasitic infections, includes a combination of at least two paraben esters and 2-phenoxyethanol as preservative |
-
2004
- 2004-06-24 CN CNB2004100254396A patent/CN1315533C/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1141810A (en) * | 1995-06-02 | 1997-02-05 | 美国家用产品公司 | Viral vaccine |
| DE20219829U1 (en) * | 2002-12-20 | 2003-05-08 | Danmarks Veterinaeinstitut Kop | Vaccine formulation against bacterial, viral, mycotic, prion or parasitic infections, includes a combination of at least two paraben esters and 2-phenoxyethanol as preservative |
Non-Patent Citations (2)
| Title |
|---|
| 猪细小病毒疫苗研究进展 吕建强等，动物医学进展，第23卷第1期 2002 * |
| 用豚鼠效检猪细粘病毒病油乳剂灭活疫苗判断标准的初步研究 张婉华等，上海农业学报，第20卷第1期 2004 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1706497A (en) | 2005-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105688202B (en) | A kind of Vaccinum Encephalitis B composition and preparation method thereof | |
| CN111840214B (en) | Temperature-sensitive hydrogel adjuvant of veterinary vaccine, preparation method and application thereof | |
| CN103071153A (en) | Ready-to-use adjuvant of livestock vaccines, preparation and applications thereof | |
| AU2019200212A1 (en) | Compositions and methods for administration of vaccines against dengue virus | |
| CN1315533C (en) | Inactivate pig parvovirus disease oil emulsion vaccine | |
| CN101549155A (en) | Porcine circovirus type II inactivated vaccine of and method for preparing same | |
| CN104248760A (en) | Vaccine composition, preparation method and application thereof | |
| CN102205120B (en) | Production method of porcine parvovirus inactivated vaccine | |
| Ko et al. | Reduction in lesion incidence in pork carcass using transdermal needle-free injection of foot-and-mouth disease vaccine | |
| Marqués et al. | The effect of foot-and-mouth disease vaccination on early pregnancy loss in beef heifers in Argentina | |
| CN101775399A (en) | Asia1 type multi-epitope recombinant vaccine of bovine foot-and-mouth disease viruses and preparation method thereof | |
| CN1704119A (en) | Oil emulsion inactivated vaccine for parvoviral diseases of pigs | |
| Smithburn et al. | Yellow Feyer Vaccination. | |
| CN102925414B (en) | Swine Japanese encephalitis virus strain and application thereof | |
| CN102716479A (en) | Pig breeding and respiratory syndrome NVDC-JXA1 strain-porcine parvovirus disease duplex inactivated vaccine and preparation method and application thereof | |
| CN102813922B (en) | Compound oil adjuvant as well as preparation method and application thereof | |
| CN101152571B (en) | Vaccine wine oil adjuvant containing momordica cochinchinensis soap and method for preparing the same | |
| CN105396131A (en) | Adjuvant for reovirus inactivated vaccine and preparing method thereof | |
| CN109395076A (en) | A kind of aftosa immunopotentiator, preparation and its application | |
| CN102719407B (en) | Porcine parvovirus BQ-C strain and application of porcine parvovirus BQ-C strain in preparation of inactivated porcine parvovirus vaccine | |
| Carter | The preparation and use of vaccines for the prevention of pasteurellosis | |
| Zinsser et al. | Studies on Typhus Fever: X. Further Experiments on Active Immunization against Typhus Fever with Killed Rickettsia | |
| Kind | Antagonism of cortisone to body temperature reducing effect of histamine. | |
| CN106771187A (en) | A kind of hog cholera genetic engineering subunit vaccine efficacy test method | |
| Depelsenaire et al. | Microarray patch delivery of un-adjuvanted influenza vaccine induces potent and broad-spectrum immune responses in a phase I clinical trial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |